Browsing by Author "Koktekir, Bengu Ekinci"

Now showing 1 - 4 of 4

Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?
(2014) Karalezli, Aylin; Kucukerdonmez, Cem; Akova, Yonca A.; Koktekir, Bengu Ekinci
AIM: To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal -conjunctival autograft transplantation (LCAT). METHODS: eighty -eight eyes of 88 patients with primary pterygium were included. Pterygia were graded preoperatively from type 1 to type 3 (type 1 atrophic, type 3 inflamed) according to the inflammatory status. The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment (group 1, 46 eyes) and additional topical bevacizumab (5 mg/mL; group 2, 42 eyes) in the postoperative period. All eyes underwent pterygium excision and LCAT. Medications were tapered and discontinued at one month. Postoperative complications and recurrence rates were recorded. RESULTS: The mean follow -up duration was 29.3 +/- 4.2mo (24-52mo) and 28.5 +/- 3.4 (24-48mo) in group 1 and 2, respectively (P>0.05). There were no statistically significant differences regarding the age or gender between groups (P>0.05). Also, the difference between groups with respect to pterygium type was not significant. During the follow -up period, recurrence developed in 2 eyes (4.3%) in group 1, whereas in one eye (2.4%) in group 2. No statistically significant difference between groups was found in recurrence rates (P>0.05). No re-operation for recurrence was necessary during the follow-up period in both groups. CONCLUSION: Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT.
Does Topical Bevacizumab Prevent Postoperative Recurrence After Pterygium Surgery with Conjunctival Autografting?
(2014) Karalezli, Aylin; Kucukerdonmez, Cem; Akova, Yonca A.; Koktekir, Bengu Ekinci; 24967201
AIM: To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal -conjunctival autograft transplantation (LCAT). METHODS: eighty -eight eyes of 88 patients with primary pterygium were included. Pterygia were graded preoperatively from type 1 to type 3 (type 1 atrophic, type 3 inflamed) according to the inflammatory status. The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment (group 1, 46 eyes) and additional topical bevacizumab (5 mg/mL; group 2, 42 eyes) in the postoperative period. All eyes underwent pterygium excision and LCAT. Medications were tapered and discontinued at one month. Postoperative complications and recurrence rates were recorded. RESULTS: The mean follow -up duration was 29.3 +/- 4.2mo (24-52mo) and 28.5 +/- 3.4 (24-48mo) in group 1 and 2, respectively (P>0.05). There were no statistically significant differences regarding the age or gender between groups (P>0.05). Also, the difference between groups with respect to pterygium type was not significant. During the follow -up period, recurrence developed in 2 eyes (4.3%) in group 1, whereas in one eye (2.4%) in group 2. No statistically significant difference between groups was found in recurrence rates (P>0.05). No re-operation for recurrence was necessary during the follow-up period in both groups. CONCLUSION: Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT.
Evaluation of Choroidal Thickness Using Spectral-Domain Optical Coherence Tomography in Patients with Migraine: A Comparative Study
(2015) Karalezli, Aylin; Celik, Guner; Koktekir, Bengu Ekinci; Kucukerdonmez, Cem; 25633615; GOE-6067-2022; HTO-3612-2023
Purpose: To assess choroidal thickness in patients with migraine and compare them with healthy controls, using spectral-domain optical coherence tomography (OCT). Methods: In this prospective case-control study, choroidal thicknesses of 20 newly diagnosed migraine patients and 20 age-and sex-matched healthy subjects were measured using a high-speed, high-resolution frequency domain (FD) OCT device (lambda = 840 nm, 26.000 A-scans/s, 5 mu m axial resolution). All patients underwent a complete ophthalmic examination before the measurements. OCT measurements were taken at the same time of day (9: 00 AM), in order to minimize the effects of diurnal variation. Results: There was a statistically significant difference in median choroidal thickness between the migraine patients (277.00 [interquartile range (IQR) 85.75] mu m) and controls (301.00 [IQR 90.50] mu m) (p = 0.012). There were significant differences at all measurement points (p<0.05 for all). Conclusions: The decreased choroidal thickness of patients with migraine might be related to the vascular pathology of the disease. Further studies are needed to evaluate the etiopathologic relationship between choroidal thickness and migraine.
Topiramate-Induced Changes in Anterior Chamber Angle and Choroidal Thickness
(2016) Karalezli, Aylin; Koktekir, Bengu Ekinci; Celik, Guner; 26020486; GOE-6067-2022
Purpose: To investigate the acute effects of topiramate on the anterior chamber angle (ACA) and choroidal thickness in patients with migraine. Methods: This prospective study included 15 eyes of 15 patients with migraine who have been scheduled to start topiramate therapy. All patients underwent complete ophthalmic examination including measurement of the ACA and choroidal thickness using a spectral domain optical coherence tomography device (Optovue Inc.) and refractive status evaluation with an autorefractokeratometer (KR-8100; Topcon) at the baseline and 1 week after starting therapy. The patients were asked to report any pain or discomfort in their eyes during therapy at the follow-up visit. Results: None of the patients experienced pain or discomfort in their eyes. The mean ACA significantly decreased at the first week of the therapy compared with the baseline levels (40.34 +/- 7.06 degrees and 36.89 +/- 6.87 degrees, respectively) (P=0.001). However, the mean choroidal thickness increased from 277.33 +/- 95.60 mu m at the baseline to 323.40 +/- 84.50 mu m at the first week (P=0.01). There was a nonsignificant increase in the mean refractive error (from -0.25 +/- 0.54 diopter [D] at the baseline to -0.38 +/- 0.49 D after 1 week) (P=0.06). Conclusions: Topiramate can acutely decrease the ACA and increase the choroidal thickness. Because these effects may be asymptomatic, patients with migraine who start this therapy should be warned to be closely followed up by an ophthalmologist.